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INTRODUCTION 
Diabetes mellitus is a metabolic disorder with features of chronic 
hyperglycemia that occurs due to defective insulin secretion or resistance 
to insulin action or both. The long term effects include end organ damage 
especially to the eyes, kidney, heart, blood vessels and nerves1. 
The global prevalence of diabetes among adults is estimated to be 
6.4% in 2010 and is extrapolated to increase to 7.7% by 2030. As an 
emerging epidemic in India, it was estimated that 62.4 million are 
diabetic in 2011 and it is proposed to increase to 101.2 million by 20302. 
The importance of this disease arises due to the fact that, many of these 
patients have an increased risk of atherosclerosis, stroke and peripheral 
vascular disease.    
Dyslipidemia in type 2 diabetes mellitus is prevalent among 72-
85% individuals.Dyslipidemia is often associated with diabetes. In type 1 
diabetes there is an increased risk of cardiovascular mortality only after 
the development of nephropathy, whereas, in the case of type 2 diabetes, 
the risk exists for many years even before the onset of biochemical 
hyperglycemia3. 
Asian Indians are associated with increased risk of coronary heart 
disease than Caucasians and 80% of deaths in diabetic individuals is 
attributed to cardiovascular disease.There are associated lipid 
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abnormalities due to relative insulin deficiency and chronic 
hyperglycemia. There is an increase in low density lipoprotein 
cholesterol, triglyceride levels, and a decrease in high density lipoprotein 
cholesterol levels4. 
Several theories have been postulated for pathogenesis of diabetes. 
The glycoxidation hypothesis, proposed that pentosidine and 
carboxymethyllysine, which are a subclass of advanced glycosolation end 
products that cause oxidative damage to long lived proteins in diabetes5. 
The free radical theory connotes that the reactive oxygen species 
leads to cellular damage through stress sensitive pathways such as 
Nuclear Factor Kappa ( NF-KB), Mitogen Activated Protein Kinase (p38 
MAPK) and hexosamine pathway which is responsible for onset of late 
complications of diabetes6. 
Of all the treatment modalities for diabetes, life style intervention 
is promoted as an effective means to prevent or delay the incidence of 
diabetes and its complications, thereby reducing the public health 
burden7. Pharmacotherapy of diabetes commonly includes usage of 
sulfonyl ureas, biguanides and thiazolidindiones. But all these synthetic 
oral drugs are laden with adverse events on prolonged use8. According to 
the diabetes association there has been an inflation of cost in 2017, since 
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2012. This may be due to a 13% increase of cost per person with diabetes 
and an overall 11% increase in prevalence of diabetes9. 
Glibenclamide, a widely used sulfonyl urea causes inhibition of 
ATP sensitive k+ channels in the beta cells of pancreas, thereby 
promoting insulin secretion.The additional effects include antiplatelet, 
antitumor and analgesic activities. Research from prior studies, show that 
glibenclamide is beneficial in counteracting the oxidative stress mediated 
cellular damage10. 
The adverse effects of oral hypoglycemic agents include 
hypoglycemia, nausea, gastro intestinal disturbances, weight gain, 
hepatotoxicity and rarely cholestatic jaundice, blood dyscrasias. Hence, 
the advantage of glycemic control is offset with the imbalance in 
lipidemic control. 
This has lead to an exponential growth in the field for research in 
herbal remedies, that have antihyperglycemic, and anti oxidant potential, 
with a minimum of adverse effects. 
The World Health Organization has enlisted 21000 medicinal 
plants, of which 2500 species are endemic to India. Around 800 species 
are reported to have antidiabetic potential, such as 
Combretummicranthium, Elephantopusscabes, Brassicajuncea to site a 
few11. 
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Annona squamosalinnis one such plant with antidiabetic potential. 
It is a small, semidecidious tree, which has a very good commercial 
importance in India. All parts of the plant such as fruits, leaves, root and 
bark are enriched with nutraceutical values. It is commonly know as                  
“custard apple” or sitaphal12. 
The bioactive components of Annona squamosa are alkaloids, 
glycosides, essential oils, flavanoids, phenolic components, saponins13. 
The other effects of Annona squamosa are its antibacterial activity, 
antigenotoxic activity, antimicrobial and antioxidant, cytotoxic, 
hepatoprotective, insecticidal, vasorelaxant and anti inflammatory 
activity14. 
As a novel attempt to cut down the complications and cost of oral 
hypoglycemic agents and provision of better glycemic control in patients 
with diabetes, this study has been performed to evaluate the 
antihyperglycemic effect of the aqueous extract of the leaves of Annona 
squamosa (linn) in diabetic rat models. 
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AIM 
 
To study the antihyperglycemic activity of aqueous extract of 
leaves of Annona squamosa in Streptozotocin induced diabetic rats. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW  
OF  
LITERATURE 
  
6 
REVIEW OF LITERATURE 
 
 “Diabetes is a dreadful affliction, being a meltdown of the flesh 
and limbs into urine. Life is short, unpleasant and painful, thirst 
unquenchable, drinking excessive and disproportionate to the large 
quantity of urine, for yet more urine is passed.” -Aretaeus of 
Cappadocia. 
The facets of Diabetes Mellitus are ever changing and challenging, 
throughout the ages. It was presumably, first described by Physician Hesy 
Ra in an Egyptian papyrus (1500 B.C), which was discovered by George 
Ebers. Apollonius of Memphis (250 B.C) used the term ‘Diabetes‘. The 
sugary nature of urine was detailed by Thomas Willis in 1675 as “Pissing 
evil” and John Rollo (1797) nomenclature the term “mellitus” - which 
meant honey in Latin. The contributions to this history were also 
provided by Indian physicians Charaka and Sushruta around 400-500 
B.C, who noted the sweetness of urine in the disease afflicted patients. 
Again, the treatment of diabetes was empirical and accomplished 
with dietary manipulations. A mix of hierde, nardum, mastix, emetics, 
narcotics, fenugreek, wormseeds were prescribed along with a diet of 
milk, bread and boiled barley water. Apollinaire Bouchardat, considered 
by some as the father of diabetology, insisted on reduction of 
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carbohydrates, intake of green vegetables and intelligent use of exercise 
in order to bring the disease under control15. 
 In the current world, diseases like diabetes, hypertension and 
coronary vascular diseases have increased several fold, even claiming to 
be the ‘epidemics’ of this century, mainly due to changes in lifestyle and 
nutrition. 
Epidemiology 
 Worldwide estimates projected for the year 2030, show around 366 
million people may be affected with diabetes mellitus. The prevalence 
was assumed to be more in urban areas and the age range in developing 
countries was between 45 to 64 years. The higher prevalence is most 
likely due to increasing urbanization and longer life span. 
 India tops the list of countries with the highest estimates, to project 
from 31.7 million to 79.4 million in 2030. Indians show a number of 
peculiar features which make them highly susceptible to diabetes16. 
Adults in urban areas of Tamilnadu have a diabetic prevalence of 13.7% 
as compared to the rural population (7.8%)17. Greater urbanization, 
growth of middle class and increased life expectancy will further increase 
the prevalence in near future. 
A younger age of onset of diabetes had been noted in Asian 
Indians. According to the ICMR, 23% of diagnosed youth with diabetes 
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had type 2 diabetes, which was linked to obesity.The clinical implication 
is that, given their prolonged life span, they have a greater chance of 
developing the chronic complications of diabetics18. 
 In terms of burden of disease, measured in Disability Adjusted Life 
Years (DALY), cardiovascular diseases and diabetes mellitus account for 
14% of the total disease burden by the year 2030. The economic burden, 
in terms of accumulated losses in gross domestic product (GDP) between 
2006 and 2015 can be as much as $17 billion in India, due to coronary 
vascular disease and diabetes alone19. 
 The prevalence of metabolic syndrome in Tamilnadu population is 
compared sex wise with U.S population and it was around 37% in males 
(vs 43% U.S) and 35% in females (vs 38% U.S)20. 
 Poor glycemic control increases the cholesterol levels, triglycerides 
and low density lipoprotein levels, which in turn fostered the 
development of cardio vascular diseases in diabetic patients. Optimal 
care, routine self monitoring of blood glucose, lipid profile assessment 
are key factors, to maintain diabetic dyslipidemia under control21. 
 Diabetes is an “iceberg” disease. The increase in prevalence and 
incidence of Type 2 diabetes has been especially dramatic in developing, 
newly industrialised countries and countries in economic transition. 
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Migrant studies indicate that a genetic/ethnic vulnerability of Indians is 
associated with a higher risk of onset of diabetes and its complications.  
 The prevalence rises steeply with age especially in the middle years 
of life. The concordance rate in identical twins who developed Type 2 
DM was approximately 90 percent, whereas in Type 1 DM, it was around 
50 percent.  
Type 1 DM is strongly associated with HLADR3 and DR4. 
Increasing BMI, weight gain, waist to hip ratio are powerful indicators 
for subsequent risk of Type 2 DM. Sedentary life style and lack of 
exercise, along with high saturated fat intake are other important 
environmental risk factors for development of Type 2 DM. Protein 
energy malnutrition in early infancy/childhood can lead to partial failure 
of β cell function, thus causing impaired carbohydrate tolerance. Rubella, 
mumps and human coxsackie virus B4 are considered triggers in β cell 
destruction22. 
Definition 
 Diabetes mellitus is a metabolic disorder, occurring due to absolute 
or relative insulin deficiency, resulting in chronic hyperglycemia and 
attendant long term micro vascular and macro vascular complications 
such as nephropathy, neuropathy, retinopathy and atherosclerosis. 
Occasionally, the diagnosis of diabetes may be spotlighted because of 
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other co-morbidities such as urinary tract infections, furunculosis, 
coronary artery disease etc.., This complicates the disease further, as the 
patient may have a long asymptomatic period of 5 to 15 years but present 
for the first time along with the above mentioned complications23. 
Classification:24 
1)  Type I Diabetes  
         Idiopathic or immune mediated 
2)  Type II Diabetes 
Insulin resistance with a relative insulin deficiency  
3) Other specific types 
A) Genetic defects  
i. Hepatocyte nuclear transcription factor (HNF)4 alpha    
(MODY 1) 
ii. Glucokinase (MODY 2) 
iii. HNF-1 alpha (MODY 3) 
iv. Insulin promoter factor (IPF) 1 (MODY 4) 
v. HNF-1 Beta (MODY 5) 
vi. Neuro D1 (or) Beta 2 (MODY) 
vii. Type A insulin resistance 
viii. Leprechaunism 
ix. Lipodystrophic diabetes 
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B) Diseases of the exocrine pancreas 
i. Trauma / Pancreatectomy  
ii. Pancreatitis 
iii. Hemochromatosis 
iv. Neoplasia  
v. Cystic fibrosis 
C) Endocrinopathies 
i. Cushing’s Syndrome  
ii. Hyperthyroidism  
iii. Acromegaly  
iv. Phaeochromocytoma 
v. Glucagonoma 
vi. Somatostatinoma 
D) Drug (or) Chemical Induced  
i. β – adrenegic agonists  
ii. Glucocorticoids 
iii. Thyroid hormone 
iv. Nicotinic acid 
v. Diazoxide 
vi. Thiazides 
vii. Second generation antipsychotics 
viii. Protease inhibitors 
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E) Infections  
i)  Congenital rubella 
ii)  Cytomegalovirus 
F) Rare causes  
i) Anti insulin receptor antibodies 
ii) Lawrence moon biedel syndrome 
iii) Porphyria 
iv) Prader-willi syndrome 
4) Gestational diabetes mellitus  
Homeostatic regulation of glucose25  
 Blood glucose must be well maintained and tightly regulated within 
a normal range so as to provide an uninterrupted supply of glucose to the 
nervous system even under extremes of situations. This is due to the fact 
that the brain depends on the liver for a constant supply of glucose for 
adenosine triphosphate (ATP) production, since, it has little capacity to 
store energy.  
 The glucose levels in blood are maintained on a fine balance 
between the absorption of glucose from food, and its peripheral utilisation 
especially by brain and skeletal muscle. 
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After a carbohydrate meal, the homeostasis is maintained by  
1) Suppression of hepatic gluconeogenesis  
2) Stimulation of glucose uptake by liver and peripheral tissues  
 Insulin is the physiological regulator of glucose metabolism. It is 
released in response to a meal along with a number of factors such as 
glucagon like peptide and gastrointestinal peptide.The role of these 
factors is to augment insulin release, a phenomenon known as “incretin 
effect”. 
 Insulin stimulates glucose uptake in skeletal muscle and fat through 
the glucose transporter GLUT-4.Vice versa, when intestinal glucose 
absorption is reduced, there is excessive hepatic gluconeogenesis and 
glycogenolysis, to maintain blood glucose levels. 
Adipocytes regulate conversion of stored triglycerides to fatty 
acids. Adipocytes increase the glucose uptake in a fed state through 
insulin permissive action. 
 Though type 1 and type 2 diabetes present with similar features 
their etiology, immunological basis and pathogenesis varies widely, 
hence posing a challenge in their pharmacotherapeutic options. 
Pathogenesis of Type-1 Diabetes  
It is an auto immune disease associated with progressive 
destruction of pancreatic β – cells by T cell mediated immunity. An 
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interplay of both genetic and environmental factors is involved in the 
development of susceptibility to this disease. Of major importance are the 
polymorphic HLA-DRBI and HLA-DQB1/DQA126. 
Candidate gene studies also identified the insulin gene on 
chromosome 11, as the second most important genetic susceptibility 
factor accounting for 10% of the cases27. The allele for the gene encoding 
CTLA-4-cyto toxic T lymphocyte antigen, on chromosome 2q33 is the 
third susceptible locus. Others include a variant of PTPN22, which 
disinhibits T-cell activation.  
The popular candidates for environmental factors include 
- Enterovirus 
- Rotavirus 
- Rubella 
The autoantigens implicated in future risk of acquiring type I 
diabetes are, glutamic acid decarboxylase (GAD65), a protein tyrosine 
phosphatase like molecule (IA-2) and insulin. People with IA-2 
antibodies have a high positive predictive value among the three 
mentioned above. 
Pathogenesis of Type 2 Diabetes  
Unlike type 1 diabetes, there is no evidence of an autoimmune 
basis for this disease. The triad of features include-  
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- Genetic factors 
- Environmental factors, and 
- Proinflammatory state. 
The risk factors include28, 
i) Family history of diabetes 
ii) Obesity 
iii) Age >42years 
iv) Ethnicity (Asian-American , African-American) 
v) Previously diagnosed impaired fasting glucose (or) impaired 
glucose tolerance 
vi) H/O gestational diabetes mellitus (or) delivering of a baby over 
4.5kg 
vii) Hypertension (BP ≥ 140/90) 
viii) High density lipoprotein ≤35 mg % 
ix) Triglyceride ≥250mg % 
x) Polycystic ovarian syndrome 
xi) Stress induced 
- Infection 
- Myocardial infarction 
- Trauma 
- Pregnancy 
- Stroke  
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- Emotional stress 
- Drugs (Glucocorticoids, estrogens, sympathomimetics , 
nicotinic acid) 
Genetic factors: 
          First degree relatives have 5 to `10 fold higher risk of developing 
type 2 diabetes rather than family history naïve patients 
The two cardinal features are29 
i) Insulin resistance  
ii) β cell dysfunction  
Of these, insulin resistance is the forerunner and it is accompanied 
by compensatory β cell hyperfunction and hyperinsulinemia in the 
beginning. Insulin resistance leads to, 
i. Failure of inhibition of endogenous hepatic gluconeogenesis 
ii. Failure of glucose uptake and glycogen synthesis post prandially 
iii. Failure of inhibition of lipoprotein lipase in central adipose 
tissues free fatty acids are “toxic”. They attenuate insulin receptor 
signaling. 
The functional defect includes reduced phosphorylation of tyrosine 
of insulin receptor and IRS proteins.This results in reduced GLUT 4 
expression on peripheral cells. Furthermore, the levels of adiponectins is 
reduced in obesity, which contributes to insulin resistance. 
17 
       The inflammatory component includes secretion of 1L-1β, which 
mediates further release of proinflammatory cytokines from macrophages 
and islet cells promoting insulin resistance. 
The β cell dysfunction is promoted by several mechanisms such as, 
(i) Lipotoxicity 
(ii) Glucotoxicity 
(iii) Abnormal incretin effect leading to reduced GIP and GLP-1 
(iv) Amyloid deposition in the islets. 
Clinical features30:- 
The symptoms of diabetes mellitus include 
i. Excessive thirst 
ii. Excessive urination 
iii. Excessive hunger 
iv. Lethargy 
v. Sudden weight loss 
vi. Drowsiness  
vii.  Blurring of vision 
viii. Dry mouth 
Increased urination and thirst are due to hyperglycemia. Osmotic 
diuresis leads to glycosuria and loss of water and electrolytes in urine. 
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Increased hunger – The body does not have enough insulin to 
ensure glucose uptake by the skeletal muscles and organs, hence 
depleting them of ATP (adenosine triphosphate), leading to hunger. 
Weakness of muscles is due to total body potassium loss and 
catabolism of muscle proteins. Neurotoxicity from sustained 
hyperglycemia leads to temporary dysfunction of peripheral sensory 
nerves causing paresthesias. 
Prolonged exposure of the ocular lens to hyperosmolar fluids leads 
to blurred vision. In certain obese individuals the Type 2 diabetes will be 
occult for some time, detected only with routine laboratory studies. 
Chronic skin infections are common. Recurrent furunculosis, 
urinary tract infections may occur. Some women present with pruritus 
and symptoms of vaginitis. Balanoposthitis may occur in males. 
Centripetal distribution of fat in the abdomen, chest, neck and face 
might occur. Acanthosis nigricans (hyperpigmented and hyperpkeratotic 
skin in the axilla, groin and back of neck) is a sure sign of insulin 
resistance.Cutaneous features of diabetes include Necrobiosis 
lipoidicadiabeticorum and dermopathy. 
Hypertension (50%) and obesity(70%) are common clinical 
findings in patients with diabetes. Poor glycemic control is indicated by 
eruptive xanthomas on flexor aspect of limbs. Hyperchylomicronemia 
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with lipemiaretinalis might occur in uncontrolled Type 2 diabetes with 
familial hypertriglyceridemia. 
Characteristics of Type 1 and Type 2 Diabetes 
Features Type 1 Type 2 
1. Onset Abrupt Progressive 
2. Endogeneous 
insulin Low to absent 
Normal, elevated or 
depressed 
3. Ketosis Common Rare 
4. Age at onset Any age Vast majority adults 
5. Bodymass Usually non obese Obese 
6. Treatment Insulin Diet, oral hypoglycemics, insulin 
7. Family history 10% - 50% 30% 
8. Twin 
concordance 30% - 50% 70% - 90% 
9. HLA association HLA–DR, HLA DQ Unrelated 
10. Auto antibodies Present in >85% 
Absent, except in patients 
with coincidental type 1 
diabetes 
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Diagnostic criteria31:- 
Blood glucose 
value 
Normal 
glucose 
tolerance 
Impaired 
glucose 
tolerance 
Diabetes mellitus 
Fasting plasma 
glucose (mg/dl ) <100 100 – 125 >126 
2 hrs after glucose 
load (75g in 300ml 
of water) (mg/dl ) 
<140 >140 -199 >200 
HbA1c (%) <5.7 5.7 – 6.4 >6.5 
  
Additionally, due to increased prevalence of dyslipidemia in 
diabetes, it is instructive to screen the lipid profile on an annual basis, 
especially in type 2 diabetes. 
 Total cholesterol, HDL cholesterol and triglycerides should be 
checked in fasting state and only after achieving good glycemic control to 
obviate the false need of lipid lowering agents. The LDL levels can be 
calculated using the Friedewald’s formula.  
The ADA guidelines states that the primary goal is to lower the 
LDL cholesterol levels below 100 mg/dl and in patients with 
cardiovascular risk, the LDL target levels should be < 70 mg/dl. Raising 
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HDL values >40 – 50 mg/dl is deemed desirable. A target level of <150 
mg/dl is proposed for triglycerides32. 
Complications of Diabetes Mellitus33: 
Acute complications: 
1. Diabetic ketoacidosis (DKA) 
2. Hyperglycemic hyperosmolar syndrome (HHS) 
3. Iatrogenic hypoglycemia 
Underlying mechanism for DKA and HHS includes a reduction in 
circulating insulin and increase in catecholamines, cortisol, glucagon and 
growth hormone. 
The patients present with 
1. Hyperglycemia   –  Due to increased gluconeogenesis 
- Increased glycogenolysis 
- Reduced glucose utilisation 
2. Keto acidosis – due to  
- Increased lipolysis 
- Increased hepatic fattyacid  oxidation 
Chronic complications 
Micro vascular complications 
1. Diabetic neuropathy 
2. Diabetic retinopathy  
3. Diabetic nephropathy 
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Macro vascular complications 
1. Cerebro vascular disease 
2. Coronary artery disease 
3. Peripheral artery disease 
4. Erectile dysfunction 
5. Gangrene of lower extremities 
Endothelial dysfunction is implicated as the principle cause of 
micro vascular and macro vascular complications 
i. Decreased production of Endothelium derived relaxing 
factor (EDRF) 
ii. Increased inactivation of EDRF 
iii. Impaired diffusion of EDRF to smooth muscles 
iv. Impaired smooth muscle responsiveness to EDRF 
Mechanisms for hyperglycemia induced damage:- 
 Five major mechanisms result in hyperglycemia induced end organ 
damage  
A.Increased polyol pathway flux  
The polyol pathway contains the enzyme aldose reductase which 
utilizes NADPH as a cofactor to convert glucose to sorbitol. Excessive 
depletion of NADPH causes reduced regeneration of glutathione, which 
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requires NADPH as a cofactor. The final outcome is increase in reactive 
oxygen species due to reduced scavenging by glutathione.  
B. Increased intracellular formation of AGEs (Advanced Glycation End 
products) 
These AGE’s will alter the function of intracellular proteins and 
plasma proteins which will in turn lead to induction of ROS, which will 
activate NF-KB (nuclear factor KB) causing pathological changes in gene 
expression. 
C. Increased expression of the receptors for the AGE’s  
D. Increased PKC (Protein Kinase) activation 
Due to enhanced de novo synthesis of DAG (diacyl glycerol) it 
depresses the production of NO (nitric oxide by eNOS (endothelial nitric 
oxide synthase) and increases ET-1 (endothelin) production, thereby 
causing decrease in renal and retinal blood flow. 
E. Overactivity of the hexosaminepalthway 
Glucose is shunted into hexosamine pathway. Fructose 6 phosphate 
is diverted from glycolysis, to provide a substrate for Glutamine Fructose 
6 phosphate Amino Transferase (GFAT). This GFAT in turn produces 
UDP-N acetyl glucosamine which is used for post translational 
modifications on certain cytoplasmic and nuclear proteins leading to an 
increased production of TGF-β (Transforming growth factor β) and       
24 
PA1-1 (Plasminogen activator inhibitor). The end result being capillary 
occlusion and vascular occlusion34. 
Treatment modalities of Diabetes Mellitus:- 
• Life style modification 
• Diet 
• Insulin 
• Oral anti diabetic agents 
Lifestyle modification :- 
Patient centered approach and individualised treatment are the 
pillarstones in maintaining a comprehensive glycemic control. Lifestyle 
intervention with a focus on increased physical activity must be 
reinforced as a general diabetes education to all patients. Even a modest 
weight loss (5-10%) contributes to achieving improved glycemic control 
and has a positive long term impact on cardiovascular risk factors. 
150 minutes/week of moderate aerobic exercises, flexibility 
training should be advised. Since the high glycemic response that occurs 
after a meal is implicated in microvascular risk enhancement, it is better 
to perform exercise an hour after meal35. 
The mechanisms by which exercise regulates glucose levels are, 
• Stimulation of GLUT – 4 transporters in muscle and 
improved glycogen storage. 
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• Improved overall insulin sensitivity  
• Promotion of oxygen delivery to peripheral tissues  
• Elevation of 2,3 DPG levels in RBC 
• Reduction of HbA1c 
 
 Some guidelines to improve glycemic response and avoid 
hypoglycemia are, 
• If glucose level is <100 mg/dl, patient should eat a snack 
• If fasting glucose level is >300 mg/dl, exercise is 
contraindicated 
• Monitoring of plasma glucose after exercise must continue 
up to 6-12 hrs after exercise, because exercise induced 
hypoglycemia may be protracted. 
• Reduction of premeal insulin dose 
• Avoid massage or exercising the body part that has received 
subcutaneous insulin as it might foster rapid absorption and 
result in hypoglycemia 
• Children and adolescent girls have greater variations in 
blood glucose levels due to play activity and hormonal 
changes respectively36. 
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Dietary Modification37 : 
Diet plays a critical role in diabetes. A few guidelines for dietary 
management are, 
• Regular meals timings  
• 8-10 servings of vegetables to be consumed.  
• 5-6 servings per day are better than 2-3 large sized meals 
• Complex carbohydrates are better than simple sugars. 
• Total carbohydrate intake should constitute 50-55% of total 
calories 
• Total protein intake around 15-20% of calories and 25-30% 
calories should be provided from fat. 
• Carbohydrates breakup is a follows: 
 25%-in breakfast 
 30%-in lunch 
 30%-in dinner 
 15%-in evening snack 
• Fiber intake should be around 14 g /1000 k Cal 
• Fat Sources from MUFA (Mono Unsaturated Fatty Acid), PUFA 
(Poly Unsaturated Fatty Acid) and EPA ( EicosaPentanoic Acid) 
are recommended 
• Saturated fat must be < 7% of total calories. 
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• High biological value foods are preferred  
• Salt intake must be reduced to < 1.5g / day 
• Allowance for sufficient vitamin C, vitamin B6, vitamin E, zinc, 
chromium, magnesium, carotenoids and flavanoids must be 
provided. 
• Limitation on alcohol consumption to one drink per day for women 
and 
2 drinks / day for men. 
• Avoidance of foods with high glycemic index such as glucose, 
sugar, honey, parathas, pastries, mangoes, bananas, sweet potatoes. 
• Generous intake of green leafy vegetables, radish, tomatoes and 
soups, due to their lower glycemic index. 
Yoga :- 
 Improves glycemic control 
 Improves insulin sensitivity 
 Relieves stress 
Pharmacotherapy :- 
Insulin:- 
The discovery of insulin in 1921 by Banting and Best and its 
subsequent utilization on Leonard Thompson in 1922, was a seminal 
event in the history of diabetes. Insulin is a protein comprising of 2 
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polypeptide chains: A-with 21 amino acid residues and B-with 30 amino 
acid residues, both linked by an intra chain disulfide bridge at residues 6 
and 11 respectively38. 
Human insulin is now produced by recombinant DNA technology 
using E.coli (or) yeast. Dry human insulin is a microcrystalline powder 
that precipitates at pH of 5.4 but is soluble at pH 2-3. 
The international unit conversion is as follows; 1 I.U. of insulin 
corresponds to 38.5mg dry substance. 
Insulin is recommended for 
 Type1 Diabetes mellitus and 
 Type2 Diabetes mellitus, who are unresponsive to diet, 
lifestyle intervention and oral anti diabetic drugs. 
Target tissues of insulin include, 
• Liver  - Increases glucokinase activity 
      -Traps glucose in hepatocytes 
       - Enhances glycogen synthesis and fatty acid synthesis. 
• In skeletal muscle and adipose tissue - Increases translocation of 
GLUT 4 from intracellular vesicles to cell adipose surface. 
• In skeletal muscle - Increases amino acid uptake and promote 
protein synthesis and promotes glycogen storage. 
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• In adipose tissue - Increases expression of lipoprotein lipase 
-Deactivates hormone sensitive lipase 
-Net result is increase in triglyceride synthesis. 
Mechanism of Action of Insulin:- 
Insulin acts through a cell membrane linked tyrosine kinase 
receptor. 
On ligand binding, tyrosine kinases autophosphorylate, thereby 
leading to phosphorylation of IRS-2(Insulin Receptor Substrates), which 
are required for further downstream signalling events. 
The pancreatic β cells, contain 𝐾ା/ATP channel, which is an 
octamer composed of Kir 6.2 and SUR1 subunits. ATP binds to Kir 6.2 
and inhibits it, leading to insulin secretion. This ATP is made available 
via GLUT2 transporters in the cell membrane which carry glucose inside 
the cell, after a meal. 
Inhibition of K+/ATP channel eventually reduces plasma 
membrane K+ conductance, thereby causing membrane depolarisation by 
opening voltage gated Ca2+ channels, Further influx of calcium inside the 
cell, leads to vesicular exocytosis of insulin39. 
GLP-1, G1P, parasympathetic activation are other factors that 
inhibit K+/ATP activity. 
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Classification of insulin preparations40 
Rapid acting : 
 Insulin glulisine 
 Insulin aspart 
 Insulin lispro 
Short acting : 
 Regular ( soluble ) insulin 
Intermediate acing: 
 Insulin zinc suspension 
 Isophane Insulin 
Long acting : 
 Insulin glargine 
 Insulin determir 
 Ultralente insulin 
Insulin analogues :- 
        They are ultra rapid and long acting insulin analogues obtained by 
recombinant DNA technology with minor substitutions in the amino acids 
of chain A and/ or chain B.Their advantages include, 
 Low incidence of hypoglycemia 
 No variation in absorption despite difference in site of 
injection 
 Controls post prandial hyperglycemia 
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 Rapidly absorbed. 
 Longer acting analogue, providing a continous low peakless 
concentration of insulin. 
 Lesser weight gain 
 Lesser hypoglycemic episodes between meals 
Adverse effects of insulin  
1. Hypoglycemia 
     Type 1 Diabetes mellitus, elderly diabetics, people with diabetic 
nephropathy and patients on intensive insulin regimen are at high risk for 
hypoglycemia. 
2. Ig E mediated insulin allergy 
3. Lipodystrophy 
4. Weight gain of 2-4 Kg. 
5. Loss of usual accommodation 
6. Edema 
7. Precipitation of peripheral neuropathy 
8. Insulin resistance. 
Oral anti-diabetic agents :- 
 Orally administered anti diabetic agents can be used as 
monotherapy (or) combined with other classes of oral anti diabetic agents 
(or) with insulin in certain refractory cases41. There has been an 
exponential burst in the development of newer agents, which are both a 
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boon and a bane to the physicians, who are loaded with a number of 
complex medications to choose from. 
Classification42:- 
1) Insulin secretagogues:- 
(Bind to SUR) receptor and stimulate insulin secretion) 
 Sulfonyl ureas  
 Meglitinides 
Dipeptidyl peptidase 4 (DPP 4) inhibitors 
2) Insulin sensitisers :- 
 (Increase peripheral uptake of glucose) 
 Biguanides 
 Thiazolidinediones 
3) Inhibitors of intestinal absorption of glucose 
 - Alpha glucosidase inhibitors 
4) Incretin Mimmetics : 
 GLP -1 receptor agonists 
5) Newer drugs : 
Sodium glucose co transporter (SGLT2) inhibitors  
 Bromocriptine 
 PPAR alpha and PPAR gamma inhibitors  
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Background on Oral hypoglycemic agents  
 In 1926, Frank and his colleagues synthesized “Synthalin” a 
guanidine derivative as the first orally active anti diabetic drug. 
Unfortunately, it was deemed excessively toxic and was withdrawn. 
In 1940, August Loubatiere’s, afrench pharmacologist, discovered 
sulfonylurea from a sulfonamide derivative. He noted that an intact (or) a 
partially functioning pancreas was essential for the activity of 
sulfonylureas. Carbutamide was the first clinically used derivative but 
was withdrawn due to bone marrow toxicity. It was followed in 1957 by 
Tolbutamide. 
Phenformin joined the race in 1959, as the first Biguanide. It was 
followed by metformin, which was not marketed until 1994 in the 
American market. 
 Thiazolidinediones were introduced in 1994. The recent ones to 
join the foray are the GLP -1 agoinst (exenatide) (or) DPP4 inhibitors, by 
the year 2005. Since then, they have paved way for SGLT 2 inhibitors 
and the search for an ideal anti diabetic agent is intensive as always43. 
Sulfonylureas :- 
 They play a role in treatment of non obese type 2 diabetic patients 
in whom metformin is contraindicated (or) metformin is unable to 
achieve glycemic control as monotherapy. 
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First Generation drugs :- 
 Chlorpropamide, Tolbutamide, Acetohexamide, 
 Tolazamide.  
Second Generation : 
 Glibenclamide, Gliclazide, Glimepride, 
Glipizide.  
Mechanism of Action44 : 
 They require residual pancreatic beta cell activity. They act by 
increasing the plasma insulin levels and reduce the hepatic clearance of 
insulin. 
 They bind to sulfonyl urea receptors (SUR-1) of the K+/ATP 
dependant channel present in the cell membrane of beta pancreatic cells. 
They inhibit the above mentioned channel, thereby blocking K+ 
conductance via the channel. This leads to depolarization of cell 
membrane, causing a massive influx of Ca 2+ into the cytosol, through 
voltage activated calcium channels. 
 The inflow of calcium into the cell causes actin myosin filament 
contraction and extrusion of the intracellular vesicles containing insulin. 
 The SUR 1 is a member of the ATP binding cassette (ABC) super 
family and it has a high affinity for glibenclamide. SUR 1 is highly 
expressed in the pancreatic β cells and in the brain. 
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The other minor mechanisms of sulfonyl ureas include 
 Stimulation of hepatic gluconeogenesis  
 Increase in number of insulin receptors 
 Increased sensitization of insulin receptors. 
The extra pancreatic effects include 
 Enhanced insulin action on liver  
 Inhibition of triglyceride lipase. 
 Inhibition of ketogenesis 
 Increased glucose uptake and oxidation.  
Unrelated to their antidiabetic activity are 
 Effects on water balance 
 Inotropism 
 Anti -aggregatory effect on platelets 
 Adenyl cyclase activation  
 Invitro inhibition of catecholamine release 
 Inhibition of adenosine monophosphate diesterase. 
The clinical implications of the above effects are not clear. 
 
36 
Pharmacokinetics : 
 Liver metabolism via cytochrome P 450 2C9 is involved in 
clearance of these drugs. They are renally excreted, so they must be dose 
adjusted in elderly people or those with impaired renal function. 
 Chlorpropamide and glyburide have longer half lives, which 
reflects their higher propensity for causing hypoglycemia. Hence it is 
better to start at a lower dose for patients with higher risk for protracted 
hypoglycemia. The sulfonylureas can cause a reduction of HbA1c by 
around 1.5% to 2%, and a fall in fasting plasma glucose by 60 to 70 
mg/dl. Sulfonylurea failure cases have low C peptide levels (or) high 
(>250mg/dl) fasting plasma glucose levels. 
 Sulfonylureas show a significant benefit in reduction of risk of 
micro vascular complications. They have negligible effect on the long 
term outcome of macro vascular complications. 
Adverse effects45 :- 
 Hypoglycemia (5%) is commonest with chlorpropamide. 
 Weight gain 
 Skin rashes 
 Gastro intestinal upset 
 Cholestasis  
 Hemolytic anemia 
 Disulfiram like reaction with 1st generation drugs. 
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Drug interactions : 
Competitors for plasma protein 
binding Warfarin ,Salicylates, 
Cytochrome P450 inducers and 
inhibitors 
Chloramphenicol, 
Cimetidine,Rifampicin 
Monoamine Oxidase inhibitors 
Competitors of renal excretion Allopurinol , Probenecid 
 
Dosing regulations :- 
 It is better to start with lower doses in elderly (or) renal / hepatic 
function compromised patients. Dosage is uptitrated every 1-2 weeks 
until the target glucose level is attained. 
Meglitinides : 
 Repaglinide 
 Nateglinide 
 These are non sulfonyl urea secretogogues of insulin. They bind at 
K+ / ATP channels on the beta cells of pancreas but at an allosteric site 
than that of sulfonyl ureas. They have a short latency period. Their 
plasma t1/2 is <1 hr and their duration of action is also shorter.  
 They preferably reduce the meal time hyperglycemia. It is 
important to avoid them, if a person has skipped a meal.The drug can be 
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given before 15 minutes of meal time and started at a low dose of 60 mg. 
The dose can be up titrated weekly, until the desired glycemic control is 
achieved (or) a maximum dose of 360mg per day is given, whichever is 
most tolerable.46 
 Metabolism is via CYP3A4 and so precautions regarding drug 
interactions is advisable.The advantage of this group, is that, of all the 
insulin secretagogues, they have the least risk of hypoglycemia. 
Biguanides :- 
1. Metformin 
2. Phenformin 
3. Buformin 
Metformin is the only biguanide that is currently used widely in a case of 
type 2 diabetes mellitus. Phenformin and buformin were withdrawn due 
to severe lactic acidosis. The intracellular target of the drug is the 
Adenosine Monophosphate activated Protein Kinase system (AMPK)47. 
 They cause inhibition of gluconeogenesis and increase the 
sensitivity for insulin in the target tissues. They require insulin for their 
action. They reduce absorption of glucose from the intestine. They act as 
insulin facilitators in adipose tissues and skeletal muscle.The drug is used 
as monotherapy or combined with other oral antidiabetic agent, especially 
in obese type 2 diabetic patients. 
39 
Adverse events :- 
 Nausea, diarrhoea 
 Metallic taste 
 Lactic acidosis – especially in renal impairment patients, liver 
failure cases, or patients with cardiogenic / septic shock. 
 Cautious use of metformin is required if the estimated GFR 
(glomerular filtration rate) is < 45 ml / min / 1.73 m2. 
 Metformin is contraindicated if the eGFR is <30 ml/min/1.73 m2. It 
should be withdrawn temporarily before administration of anaesthesia or 
radiocontrast media. Other uses of metformin may be in polycystic 
ovarian syndrome.    
Thiazolidinediones :- 
 The glitazones were a serendipitous discovery from ciglitazone, 
which was a clofibrate analogue, screened as a lipid lowering agent but it 
accidentally lowered the blood glucose levels. Ciglitazone was withdrawn 
due to liver toxicity. Rosiglitazone and troglitazone were withdrawn due 
to hepato toxicity and cardio vascular side effects.Pioglitazone is the only 
available drug in this group. 
Mechanism of action : 
 Peroxisome proliferator activated receptor gamma is a nuclear 
receptor, which is complexed with retinoid X receptor. 
 The PPAR gamma is present in adipose tissue, muscle and liver. 
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Effects of glitazone are 
 Adipocyte differentiation. 
 Increased lipogenesis 
 Enhanced uptake of fatty acids and glucose. 
 Promotion of amiloride sensitive sodium ion reabsortpion in 
renal tubules. 
 The thiazolidinediones dimerize the PPAR gamma - RXR 
complex, and allow it to bind to DNA, thereby promoting insulin 
signaling such as increased activity of lipoprotein lipase, GLUT -4 
translocation, regulation of phosphoenol pyruvate carboxy kinase, malic 
enzyme activity and others. Therefore, it causes a recalibration of the 
glucose – fatty acid (Randle) cycle, and hence increases insulin 
sensitivity48.  
Pharmacokinetics : 
 Pioglitazone has a shorter half life of < 7 hrs. Metabolism is by 
CYP2C and CYP3A4 isoenzymes. Elimination is through bile. 
Current role of thiazolidinediones : 
 As an additive drug with metformin. The advantage is that, it 
retards the progression of impaired glucose tolerance to frank diabetes. 
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After disease onset, it reduces the requirement of insulin in a type 2 
diabetic patient.  
Adverse events : 
 Liver dysfunction that requires frequent liver function test 
monitoring  
 Weight gain 
 Edema 
 Doubled risk of fractures  
 Risk of bladder cancer 
 Headache, fatigue 
 Gastro intestinal upset 
The drug is contraindicated in children and women of child bearing age. 
Alpha-glucosidase inhibitors  
 Acarbose 
 Miglitol 
 Voglibose 
Mechanism of Action: 
The alpha glucoside enzyme functions, in the brush border of the 
intestine, to breakdown the complex carbohydrates into simple sugars, 
which are absorbed into circulation.The role of alpha-glucosidase 
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inhibitors in type 2 diabetes, is to bind reversibly to the alpha-glucosidase 
enzyme, thereby delaying the absorption of carbohydrates that are taken 
in a meal. This results in lesser post prandial hyperglycemia. 
Advantage: 
As mono therapy, these drugs do not cause hypoglycemia. The 
drugs are taken with the start of the meal. 
Adverse effects: 
 Flatulence 
 Abdominal cramps 
 Diarrhoea 
Contraindications:  
 Colon ulcers 
 Intestinal obstruction 
 Inflammatory bowel disease49 
Incretin mimmetics:- 
1. Exenatide 
2. Lixisenatide 
3. Liraglutide 
4. Albiglutide 
5. Dulaglutide 
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Dipeptidyl peptidase 4 inhibitors : 
1. Sitagliptin 
2. Vildagliptin 
3. Aloglitpin 
4. Saxagliptin 
Sodium glucose co transporter 2 inhibitors:  
1. Canagliflozin 
2. Empagliflozin 
3. Dapagliflozin 
Other drugs : 
1. Amylin analogue – Pramlintide 
2. Bromocriptine 
3. Colesevelam hydrochloride 
4. Dual PPAR alpha and PPAR gamma agonists  
Insulin mimetics :- 
GLP -1 receptors are present in beta cells, vessel walls, central 
nervous system heart, lung, kidney and GIT mucosa. 
The binding of insulin mimetics to the GLP-1 receptor will lead to 
activation of cAMP – PKA pathway and activation of guanine nucleotide 
exchange factors (GEFs). Down streamsignalling via protein kinase C 
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and phosphatidyl inositol 3 kinase also occurs. These eventually lead to a 
glucose dependent exocytosis of insulin and an increased bio synthesis of 
insulin50.   
The GLP-1 analogues are resistant to DPP 4, hence having a longer 
duration of action.They cause a 1% decrease in HbA1C levels and a 
modest weight loss of 2.5 –4 kg.They are administered as subcutaneous 
injections either daily or weekly depending on their plasma half lives. 
Adverse effects :- 
 Nausea, vomiting  
 Pancreatitis 
 Spurious association with medullary carcinoma of thyroid.  
Contraindications -Creatinine clearance < 30 ml / minute 
Limitations :- 
 Cost 
 Injection site reactions 
 Hypoglycemic episodes 
Drug interactions :- 
 Delays gastric emptying 
 Alters pharmacokinetics of antibiotics and oral contraceptives. 
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Dipeptidyl peptidase inhibitors:- 
 DPP-4 is a transmembrane glycoprotein, whose function is to 
degrade glucagon like peptide 1. The role of GLP -1 is to enhance insulin 
secretion via the “incretin” effect. Hence the DPP -4 inhibitors by 
preventing the degradation of GLP -1 increase the time of action of the 
peptide.  
 The DPP -4 inhibitors act in a glucose dependent manner, hence, 
they pose a negligible risk of hypoglycemia, when used as monotherapy 
in type 2 diabetes patients. But the risk of hypoglycemia is present if they 
are combined with insulin / sulfonylureas.  
The medications are taken once (or) twice daily as oral 
formulations. They have a renal mode of elimination, except linagliptin, 
which has a predominant hepatobiliary clearance. Saxagliptin has strong 
CYP 3A4 interactions, hence caution is advised while administering it 
with CYP 3A4inhibitors such as clarithomycin, ketoconazole51. 
Adverse effects :- 
 Severe joint pain 
 Angioedema 
 Anaphylaxis 
 Increased risk of infections 
 Pancreatitis 
The drug has a good safety profile in cardio vascular patients. 
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Sodium glucose co transport 2 inhibitors52:- 
 Normal (90%) reabsorption of glucose in proximal renal tubules is 
aided by Sodium glucose co transporter 2. These transporters were 
targeted and inhibited, and this led to increased excretion of glucose in 
urine and thereby reduced the levels of blood glucose in type 2 diabetic 
patients.These drugs are approved as oral formulations for clinical use, 
their activity centers on decreasing the plasma glucose threshold by about 
90-100 mg/dl. 
Advantages:- 
 Reduction of HbA1c levels 
 Modest weight loss 
 Oral formulations 
 Lower cardiovascular mortality. 
 Reduction of blood pressure 
 They are contra indicated if estimated GFR is < 45-60 ml/ mt / 
body surface area. 
Adverse events :- 
 Genital infections 
 Urinary tract infections 
 Reduction in bone mineral density  
 Increased LDL cholesterol levels  
 Higher rates of breast and bladder cancer. 
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Pramlintide :- 
 It is approved for use in both type 1 and type 2 diabetes. It is given 
before meals.  
 Its effects are via 
 Reduction in glucagon secretion 
 Reduction in appetite  
 Prolonged gastric emptying time 
Limitations : 
 Hypoglycemic risk 
 Subcutaneous mode of delivery 
 Duration of action is only 150 minutes 
 Cannot be mixed in an insulin syringe.  
The dose ranges from 15-120 mg and is preferably uptitrated from the 
lowest dose53.  
Bromocriptine : 
Reduces HbA1c levels by 0.5% as a combination therapy with life 
style intervention or other anti diabetic drugs. Action is presumed to be 
through regulation of a dopamine induced hepatic – hypothalamic circuit, 
that reduces hepatic gluconeogenesis. 
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Adverse events : 
Nausea 
Dizziness 
Headache 
Vomiting 
1-2 kg weight gain 
Dual PPAR alpha and PPAR gamma receptor agonist 54 :- 
 Saroglitazar 
 Aleglitazar 
 These drugs improve peripheral glucose sensitivity and also have 
beneficial effects on lipid levels. They cause reduction of HbA1c levels. 
And are available as oral formulations in the dose of 2-4 mg per day. 
Adverse effects :- 
 Weight gain 
 Bone fractures 
 Precipitation of heart failure   
Goals of therapy55 : 
The holistic approach to the treatment of either type 1 (or) type 2 
diabetes is to 
 Provide symptom relief. 
 Retard the development of long term micro vascular or 
macro vascular complications. 
 Enable the patient to have an improved quality of life. 
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 Central to the success of these goals is the integrated participation 
of the patient himself, herself his/her family members, the primary health 
care provider, the endocrinologist and (or) a cardiologist / nephrologist 
/podiatrist / neurologist if essential. 
The treatment goals for adults with diabetes are as follows :- 
 HbA1C    < 7%  
 Fasting plasma glucose    < 70-130 mg/dl 
 Post prandial plasma glucose < 180 mg/dl 
 Blood Pressure    <130/80 mm of Hg 
 Low density lipoprotein   < 100 mg/dl 
 High density lipoprotein   > 40-50 mg/dl 
 Triglycerides   < 150 mg/dl 
 Achievement of the goal comes with a package of life style 
intervention, pharmacotherapy, counselling and patient education, foot 
care and self monitoring of glucose levels. 
Self Monitoring :- 
The advantages of self monitoring include56 
 Accurate records of glucose fluctuations. 
 Prior alert regarding acute hypoglycemic episodes. 
 Incentive for patients to attain glycemic control 
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 The time interval between self check-up depends on the severity of 
the disease, the type of diabetes and individual motivation. Glucometers 
with self applicable strips are available for easy use, especially after 
proper guidance and education. A continuous glucose monitoring system 
with a cable, a glucose sensor, a com–station and a monitor is also 
available for managing unstable cases, pregnancy fluctuations and for 
patients on insulin pumps.  
The umpteen number of oral antidiabetics that flood the 
pharmaceutical markets come with their own catches. They are 
ineffective in about one fifth of diabetic cases and even the drugs which 
initially produced an effect might later lead to a secondary failure. 
Further, they are laden with adverse effects, the most common being 
hypoglycemic risk. None of the above drugs can simulate a physiological 
insulin secretion nor provide a tight glycemic control.Thebiguanides have 
an increased risk of renal and hepatotoxicity. The thiazolidinediones are 
associated with cardiovascular risk and fractures.Even the latest SGLT 2 
inhibitors have an increased risk of infections and the DPP4 inhibitors, an 
increased risk of gastrointestinal complications57. 
Hence, a search for a natural drug with improved effectiveness and 
lesser adverse effects for diabetes is consistently in the forum. With the 
dawning knowledge of the adverse effects associated with allopathy, we 
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find more individuals drawn towards the alternative forms of medications 
especially the ‘herbal substances’, to heal them of ailments. 
From time immemorial, plants have been considered a valuable and 
powerful source of natural products that can maintain human health and 
many studies have been funded in the direction of natural 
therapeutics.According to the World Health Organization, medicinal 
plants are considered to be rich in lead compounds that can be developed 
into newer drugs58. 
The indigenous system of Ayurvedha, Siddha and Unani has 
catered to the needs of about 70% of the rural population. India, being the 
home ground for these medicinal plants, naturally, more focus is laid on 
developing drug from these plants. Herbal medications are preferred 
especially in chronic ailments such as diabetes, asthma, arthritis, chronic 
myalgia, wherein man has not yet mastered the disease by 
pharmacotherapy. This is further reinforced by the “Phobia” associated 
with long term use of synthetic drugs. 
All the above points has led to an increase in the trend of using 
natural products in chronic diseases. The downside of this rampant usage 
of natural products, is that, if they are not properly quality controlled, 
they might lead to contamination, inefficacy and adverse effects. 
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Annona squamosa59:- 
 Annona squamosa linn, of the family Annonaceae, is commonly 
cultured in Thailand and its origin is from South America. However, it is 
commonly found in India and is grown in gardens for its ornamental 
values and fruits.Tribal use of Annona squamosa has been recorded in a 
variety of common ailments. 
 It is a small ever green tree (or) a shrub of 7 meters in height, that 
bears edible fruits called “sugar apple”. It is also known as custard apple, 
sharifa or sitaphalam. 
 The simple alternate leaves occur singly, about 5- 17cm in length 
and they have a rounded base and a pointed tip. They are pale green on 
both surfaces. The leaf stalks are 0.4 – 2cms in length, green in colour. 
Taxonomic classification:- 
 Kingdom  : Plantae 
 Division  : Mognoliophyta 
 Class   : Magnolipsida 
 Order   : Magnoliales 
 Family  : Annonaceae 
 Genus  : Annona L. 
 Species  : Annona squamosa 
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Phytochemical constituents:- 
 The plant is reported to contain glycosides, alkaloids, flavanoids, 
tannins, phytosterols, anonaine, aporphine, glaucine, isocorydine, 
norcorydine, coryeline. The leaves are rich in anonine, borneol, 
camphene, β-caryphyllene, eugenol, farnesol, geraniol, hexacontanol, 
isocorydine, higemamine, limonine, linalool acetate, menthone, methyl 
salicylate, β-sitosterol, thymol, rutin, n-triacontanol. The leaf extract does 
not contain aminoacids or alkaloids60. 
Parts used:- 
- Fruits  
- Bark 
- Leaves 
- Root 
Pharmacological properties:- 
The presence of acetogennins were considered responsible for  
• Antimalarial 
• Immunomodulatoy 
• Cytotoxic activities 
The Presence of diterpenes was found to possess,  
Anti HIV activity 
Anti plateletaggregatory activity 
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Flavanoids were reported to have, 
Anti microbial 
Pesticidal activities 
Folkloric use of this plant was reported in instances like tumor and 
inflammation. The crushed leaves were inhaled to cure a fainting spell. 
They acted as soothers on ulcers and wounds. A decoction of the leaves 
was drunk in case of dysentery. 
The aqueous extract of leaves was reported to attenuate 
hyperthyroidism. It was used by tribes to manage diabetes. They have 
astringent properties. 
Various parts of the plant were proposed to have mollusicidal 
activity against Schistosoma species. The flavanoids in the leaf extract 
have antioxidant activity which at times, confers a hepatoprotective 
effect. 
They possess larvicidal activity against Anopheles stephensiand 
they are also active against helminthes. The acetogenins were considered 
responsible for the above mentioned effects. 
Experimental animal models for diabetes mellitus61:- 
 In 1980, Von Meringpancreatectomised a dog to study fat 
absorption from the intestine, and found that the animal developed 
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polyuria and polydipsia, which were the cardinal features of diabetes. 
Marjorie was a famous experimental canine that was used by Banting and 
Best , for insulin purification. 
Models for IDDM:- 
1. Chemically induced diabetes 
2. Hormone induced diabetes mellitus 
3. Insulin antibodies induced diabetes 
4. Viral agent induced diabetes. 
5. Surgically induced diabetes 
Genetic models:- 
1. Non obese diabetic mice. 
2. BB wistar rats. 
3. Wistar Bonn / kobori rats 
4. Cohen diabetic rat 
Chemically induced diabetes:- 
 The chemicals commonly used are alloxan / streptozotocin. It is the 
most common animal model for type I diabetes. The chemicals act by one 
of the following 3 mechanisms. 
1. β cell damage. 
2. Temporary inhibition of insulin production and / or secretion. 
3. Reduction of tissue sensitivity to insulin  
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Beta cell damage is preferred as it closely resembles the natural 
disease. 
Hormone induced diabetes mellitus:- 
 Dexamethasone is injected at a dose of 2-5 mg/kg, intraperitoneally 
in a twice daily manner, over a number of days. Rats are preferred for this 
model, whereas guinea pigs and rabbits can also be used. Corticotropin 
can be used for adrenal cortex stimulation leading to steroid diabetes. 
Insulin antibodies induced diabetes:- 
 Anti insulin antibodies are extracted from guinea pigs which are 
treated with bovine insulin along with CFA. These antibodies are injected 
as 0.25-1ml intravenous injection to rats, to obtain a diabetic cut off level 
of 300 mg %. Large doses can cause ketonemia, ketonuria, acidosis and 
fatality. 
Viral agent induced diabetes:- 
 Viruses may destroy the β cells of pancreas or they may elicit an 
autoimmune response in the body to destroy the β cells. The viruses used 
for this purpose are, 
1. RNA picornovirus 
2. Coxsaxckie B4 
3. Encephalomylocarditis virus 
4. Mengo 2t 
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5. Reo virus 
6. Lymphocytic choriomeningitis virus. 
They are inoculated into suckling mice, or cultured in mice β cells. 
Surgically induced diabetes:- 
 It can be attained by partial (or) total removal of the pancreas by 
surgery. Even in partial pancreatectomy >10% of residual tissue can 
allow for normal functioning of the gland. The results might be temporary 
for a few days to months, depending on the amount of functional cells. 
Total pancreatectomy results in an insulin dependent state. 
Limitations:- 
 Loss of α cells and δ cells of pancreas, lead to a decline in counter 
regulatory hormones such as glucagon and somatostatin. 
 Indigestion due to loss of exocrine part of pancreas 
 Technical difficulty in rats. 
Hence, a combination of surgery and chemical induced diabetes is 
preferred for increasing the reliability of the model. 
Models for NIDDM:- 
Chemicals for NIDDM induction:- 
1. Streptozotocin 
2. Adrenaline, EDTA (Ethylene diamine tetra acetic acid ) 
3. Diazoxide 
4. Thiazides 
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5. Furosemide 
6. Alloxan 
Genetic models for NIDDM :- 
A) Monogenic models of obesity and NIDDM 
i. Yellow mouse / agouti mouse  
ii.  Obese and diabetic mouse with mutation in C57BL/KSJ inbred 
strain. 
iii. Tubby mouse – mutation in the single C57BL / 6J male strain 
iv. Fat mouse – CPE fat mutation 
v. Zucker Diabetic fatty rat 
vi. WDF / Ta –Fa rat. 
vii. Koletsky and JCR ; LA – Corpulent rats. 
Polygenic models of obesity and NIDDM 
(i) New zealand obese mouse. 
(ii) Diabetic db /db mice. 
(iii) Nagoya-Shibata Yasuda mouse. 
(iv) Chinese hamster 
(v) Djungarian hamster 
(vi) Goto – Kakisaki rat 
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Genetically manipulated animal models:- 
Genes modified for insulin resistance code for 
• Insulin receptor, IRS 1 and 2, GLUT, Hexokinase, TNF α, RAS 
associated with diabetes, Fatty acid binding protein 2  
Genes modified for reduced secretion of insulin code for 
• GLUT 2, Glucokinase, Hepatic nuclear factors 
Of all the above theoretical models, the most feasible, reliable method is 
chemical induction of diabetes. 
Streptozotocin(STZ)62 :- 
Streptozotocin is an antimicrobial agent and has historically been 
used as an alkylating agent. Rakieten first described the diabetogenic 
potential of STZ. It is a 2 deoxy 2 (methyl nitrosoamino) carbonyl – 
amino) D- glucopyranose. The drug is hydrophilic, relatively stable at 
pH7.4 and at 37˚C. 
 It acts as a nitric oxide donor and causes DNA alkylation. Its          
β cell specificity is due to its selective cellular uptake and accumulation. 
Streptozotocin is a less lipophilic nitrosourea analogue, getting inside the 
β cells via GLUT 2 glucose transporter. The methyl nitrosoureamoiety, 
causes transfer of the methyl group of streptozotocin to the DNA of host 
cell, resulting in fragmentation of DNA. Additional protein glycosylation 
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and overstimulation of poly ADP – ribose polymerase causes cellular 
depletion of ATP and NAD, ultimately resulting in necrosis of the host 
cells. 
 A minor mechanism of action may be due to generation of 
superoxide and hydroxyl radicals during the hypozanthine metabolism 
thereby accelerating the process of cellular necrosis. 
Effects of STZ63:- 
• Inhibition of insulin biosynthesis 
• Inhibition of insulin secretion 
• Disruption of glucose metabolism  
• Dysfunctional glucose transport 
• Dysregulation of glucokinase activity  
Limitation:- 
• GLUT2 expression in liver and kidney, causes STZ uptake in these 
tissues, resulting in toxicity. 
• Variations in sensitivity to STZ with regard to species and strains. 
• Male rodents were more sensitive whereas female rodents were 
protected by their estradiol levels. 
• Circadian variation in STZ susceptibility. 
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Dose:- 
 A single intraperitoneal dose of 40-70 mg /kg is commonly used to 
induce diabetes in Wistar rats.The doses vary with strains. Multiple low 
doses or a single large dose of STZ can also be given as intraperitoneal or 
intravenous injections. 
Preparation -The stability is best maintained at a pHof 4-4.5. Hence the 
STZ is better reconstituted in a citrate buffer and ice cold saline 
preparation, freshly prepared and used within 30 minutes. 
Advantages of STZ over alloxan:- 
1. Greater uptake into β cells and hence greater selectivity 
2. Lesser systemic toxicity or mortality 
3. More complete suppression of β cells 
4. Better chemical stability. 
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METHODOLOGY 
 
The aqueous extract of leaves of Annona squamosa were evaluated 
for their antihyperglycemic effect, in adult male albino rats. 
The study was done in the Central animal house, Institute of 
Pharmacology, Madurai Medical College, Madurai. The Institutional 
Animal Ethical Committee of Madurai Medical College, approved the 
study on 31.05.2018. 
Study Center 
Institute of Pharmacology, 
Madurai Medical College, Madurai 
Duration of the Study 
The study period was 6 months and it was done since March 2018. 
Number of Animals used 
24 adult male albino rats weighing about 150 –200 grams 
Materials  
1. Male albino rats  
2. Streptozotocin 
3. Tab Glibenclamide 
4. Aqueous extract of leaves of Annona squamosa 
5. Glucometer and glucose strips 
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7. Oral feeding tube 
8. Syringes. 
Animals 
       Twenty four, inbred adult male albino rats of 150 – 200 g, from 
Central animal house, Madurai MedicalCollege were utilized in this 
study. The rats were equally split into four groups.Each group had six 
animals. One group was kept as control, one as standard. The remaining 
two groups were treated with the plant extract.The animals were given 
pelletfeed and water according to their needs. 
Each group of animals were housed separately.They were 
individually and distinctly marked with picric acid. The diabetic rats were 
given special care. The bottles were filled with fresh tap water every 
morning.The cages were cleaned daily and the bottom layer was refilled 
with sawdust.This was done to maintain a hygienic environment and 
prevent spread of infection in the diabetic animals. 
Streptozotocin 
Streptozotocin was procured by HiMedia Research Laboratories 
Pvt. Ltd. 
All the groups of rats received injection streptozotocin 
intraperitoneally as a single dose of 50mg/kg. 
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Glibenclamide 
Glibenclamide, a second generation sulphonyl urea was given to 
the standard group at an oral dose of 1 mg/kg/day. 
Collection of Blood Samples 
The rats were kept in the restrainer. Lateral veins were located and 
xylolwas applied to make the vein prominent. After disinfecting with 
spirit, 0.2 ml ofblood was collected using a 22 gauge needle. 
Method of Glucose Estimation 
Glucometer was used to detect the blood sugar levels. It uses the 
glucose oxidaseenzyme specific sticks. The glucose test strip was inserted 
into the glucometer. A drop of blood, withdrawn by tail venipuncture 
method, was directly placed on the strip.The results were displayed on 
screen within 15 seconds. 
Extraction Procedure 
Annona Squamosa Leaf Aqueous Extract 
Dr. Stephen, taxonomist, of American College, Madurai identified 
and certified the species as Annona leaves, which were obtained from a 
nearby farm. The crude extract was prepared in the Pharmacognosy 
department of Madurai Medical College. 
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Leaves were washed well with water.The fresh /air-dried leaves 
(25ᵒC for 5 days in the absence of sunlight) were extracted in 1 litre of 
boiling water for 2 hours. The concentrate obtained was dark brown. It 
was cooled and filtered using Whatman No.1 filter paper. The filtrate was 
centrifuged and the sediment was discarded.The supernatant extract was 
concentrated and used for the study. Each day, the necessary amount of 
extract was dissolved in distilled water and administered orally.  
Glibenclamide (1mg/kg) was similarly dissolved in distilled water 
and given daily. The standard drug as well as the test extracts of 
annonasquamosa were givenorally using oral feeding tube and the 
treatment duration was for 14 days. 
Oral Feeding Technique 
A 16 Gauge feeding tube with a blunted tip was used. The tube was 
attached to 1 ml syringe which contained the drug to be given. The 
animals were hadled with utmost care and held by the nape of their neck. 
The oral feeding tube was inserted laterally through the interdental space, 
and by gentle rotations it was placed in the oesophagus. After 
ascertaining the desired level, the drug was gently pushed inside. 
Methodology 
The study followed the guidelines of CPCSEA.After overnight 
fasting, the blood glucose level was observed for all the rats by tail 
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venipuncture method. The baseline values were normal. All the rats were 
injected intraperitoneally with 50 mg/kg of Streptozotocin. Diabetic 
status of the rats were estimated after 3 days of streptozotocin injection, 
by repeat measurement of blood glucose levels.The animal was 
proclaimed diabetic if the blood sugar was > 250 mg/dl. The rats were 
split into groups of six and housed as control, standard, test 1 and test 2 
groups. The control group received pellet diet and water. The standard 
group received the drug Glibenclamide at the dose of 1 mg/kg/day orally. 
Test 1 and test 2 groups received Annona squamosa leaf extract in the 
dose of 300 mg/kg and 600 mg/kg respectively. 
Group Study Treatment 
GROUP STUDY TREATMENT 
I CONTROL Normal feed and water 
II STANDARD Normal feed and water +Tab Glibenclamide   (1 mg/kg) oral 
III TEST -1 
Normal feed and water + aqueous extract 
of leaves of Annona squamosa  (300 
mg/kg) oral 
IV TEST -2 
Normal feed and water + aqueous extract 
of leaves of Annona squamosa  (600 
mg/kg) oral 
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The blood glucose level were estimated at baseline and on Day 1, 
Day 7 and Day 14 and the results are tabulated. ANOVA was used as the 
statistical test to detect any significant difference between the groups. 
 
 
 
  
 
 
 
 
RESULTS 
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RESULTS 
In the present study, the antihyperglycemic effect of leaves of 
Annona squamosa aqueous extract was assessed using 24 albino rats.The 
animals were equally split into four groups. They served as the control, 
standard, test 1 and test 2 groups. 
The blood glucose levels in nondiabetic rats in mg/dl - baseline 
S. No. Control Standard T1 T2 
1 130 111 112 113 
2 115 124 114 108 
3 117 134 118 130 
4 108 106 128 104 
5 152 113 100 107 
6 81 129 108 113 
 
Streptozotocin intraperitoneally in a dose of 50mg/kg was given to 
all rats.  
After 72 hours, all the animals had blood glucose values >250 
mg/dl. The first group received pellet diet and served as control. The 
standard group received Tab Glibenclamide 1mg/kg orally. The third and 
fourth groups received aqueous extract of the leaves of Annona squamosa 
in graded doses of 300 and 600 mg/kg respectively.On Day 1, the blood 
glucose levels in diabetic rats of all the groups were 
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Day one blood glucose levels in diabetic rats (mg/dl) 
S. No. Control Standard T1-300mg/kg T2-600mg/kg 
1 489 523 589 587 
2 420 554 574 593 
3 436 545 592 589 
4 465 560 565 547 
5 445 586 594 564 
6 472 578 579 583 
 
The following graph was formulated from Day 1 blood glucose levels 
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Day 7 blood glucose levels in diabetic rats (mg/dl) 
S. No. Control Standard T1-300mg/kg 
T2- 
600mg/kg 
1 453 354 424 385 
2 476 410 443 364 
3 488 425 393 370 
4 517 378 398 451 
5 481 395 410 435 
6 490 402 387 385 
 
The following graph was formulated from day 7 blood glucose values 
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The day 14 values of blood glucose were 
Day 14 blood glucose levels in diabetic rats (mg/dl)  
S. No. Control Standard T1-300mg/kg T2- 600mg/kg
1 435 98 90 114 
2 446 102 77 103 
3 459 86 131 85 
4 447 117 105 74 
5 464 71 97 93 
6 468 94 98 110 
 
The graph shows the day 14 blood glucose levels 
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Control Group 
The mean blood glucose values of diabetic rats of the control group 
were 454.55±25 on day 1, 484.1±20 on day 7 and 453.1± 12.57 on day 
14, as shown in Table No.2 
Standard group 
The mean blood glucose values of diabetic rats in the standard 
group after the administration of Glibenclamide were 557.6±22 on day 1, 
394±25 on day 7 and 94.6±15.4 on day 14 as shown in Table No.2. 
Test Group 1 (Annona squamosa extract 300mg/kg) 
The mean blood glucose values of rats that received Annona 
squamosa extract of 300mg/kg were 582.1±11 on day 1, 409±21 on day 7 
and 99.6±18 on day 14 as shown in Table No.2. 
Test Group 2 (Annona squamosa extract 600mg/kg) 
The mean blood glucose values of rats after administering Annona 
squamosa extract of 600mg/kg were 577.1± 17 on day 1 , 398.3±35 on 
day 7 and 96.5±15 on day 14 as shown in Table No.2.  
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Table -2 
Blood Glucose Levels in Diabetic Rats in mg/dl 
Group Day 1 Day 7 Day 14 
Control 
Normal pellet diet 
454.55±25 484.1±20 453.1±12.57 
Standard - 
Glibenclamide 
557.6±22 394±25 94.6±15.4 
Test 1 
Annona squamosa 
extract 
300 mg/kg 
582.1±11 409±21 99.6±18 
Test 2 
Annona squamosa 
extract 
600 mg/kg 
577.1±17 398.3±35 96.5±15 
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The following graph shows the normal baseline value, Day 1, 7 and 
14 values of all the four groups as mean average respectively. 
 
 
 
ANOVA was calculated between the groups and it showed no 
significant difference at their baseline values.The analysis of variance 
conducted after 14 days of treatment showed a significant difference               
(p < 0.001) between the groups.  
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The following line graph shows the blood glucose levels of the 
control group of diabetic rats during the study duration. 
 
 
The following graph compares the blood glucose levels of the test 1 
group with the control. 
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The following graph compares the blood glucose levels of the test 2 
group with the control group of diabetic rats. 
 
 
The following graph compares the blood glucose levels of the treatment 
groups with the control group of diabetic rats. 
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Day Control Std T1 T2 
Baseline 117.1±23.5 119.5±11.11 113.3±9.4 112±9.2 
Day 1 458±6.1 554.1±3.7 583.3±5.0 580.8±5.1 
Day 7 486.1±6.1 391.8±5.0 403.3±5.3 389.8±1.3 
Day 14 453.1±39.7 94.6±15.4 99.6±18 96.5±15 
 
A post hoc test conducted on day 14 showed the difference was 
significant in the standard group >annona 600mg/kg group >annona 300 
mg/kg group, when compared with the control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
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DISCUSSION 
 Diabetes is a global endocrine disorder, which is rapidly emerging 
as an “epidemic” in developing countries like India, which is being 
converted into a world capital for this disease. The initial launch pads of 
this disease are deficiency of insulin (or) insulin resistance, resulting in 
hyperglycemia. Their long term effects include increased oxidative stress, 
dysfunctional lipid levels and end organ damage of the renal, retinal, 
nervous and cardiovascular system64. 
 In the long run, this disease affects the quality of life and curtails 
life span. The comprehensive management of diabetes includes diet, life 
style intervention, along with pharmacotherapy, like parenteral insulin 
(or) usage of oral anti diabetic agents. Until now, the 
pharmacotherapeutic field is ever expanding and effective in maintaining 
a tight glycemic control. The downside is their harmful side effects. 
 Hence, alternative forms of treatment are being tried with 
indigenous medicinal plants. More that 400 plant species have been 
indentified to have hypoglycemic activety with supporting literature. 
Most of the plants contain additional beneficial properties and lack the 
adverse effects associated with the drugs6. Artemisia pallens, 
Bidenspilosa, Allium Cepa, Aloe babadensis are a few plants with proven 
anti diabetic potential66. One such plant is Annona squamosa (Custard 
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apple), and the leaves of this plant, were taken in graded does and 
evaluated for its anti hyperglycemic effect in streptozotocin induced 
diabetic rats. 
 Initially, a group of 24 adult male albino rats were housed and 
divided into 4 groups of six each, as the control, standard, test 1 and test 2 
groups respectively. The animals were made diabetic by streptozotocin 
intraperitoneal injection. 
   In comparison with the untreated group, Annona treated groups 
showed a remarkable fall in blood glucose levels on day 7 and day 14. 
The values of test 2, were comparable with that of standard group. 
 ANOVA was calculated between the groups and it showed no 
significant difference at their baseline values. The analysis conducted at 
the end of the study, showed a significant difference between the groups 
at a p value of < 0.001. 
 A post hoc analysis was conducted, which showed the statistical 
difference was more with standard group > Test group 2 > Test group 1, 
when compared with the control group. 
 Kaleem et al (2008), reported that the activity of the leaves of 
Annona squamosa might be through an enhancement of insulin release 
from beta cells of pancreas or it may be due to increased GLUT4 uptake 
of glucose from plasma to peripheral tissue. An increase in the levels of 
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insulin and C-peptide were also noticed in the groups treated with plant 
extract, when compared with the sham group. It further showed an 
increase in the serum total protein and albumin levels, because of 
incorporation of the amino acids into proteins, by insulin67. 
 Gupta et al, further suggested that the aqueous extract of leaves of 
Annona squamosa, increases insulin release even from partially destroyed 
pancreatic cells, by probably regenerating the beta cells (or) release of 
stored insulin from granules68. It was suggested to improve glucose 
tolerance and the extract reduced the levels of total cholesterol, LDL, 
VLDL in diabetic animals and also increased the levels HDL cholesterol. 
 In vitro studies from aqueous extract was shown to inhibit  
theglucose 6 phosphatase enzyme activity, thereby preventing 
glycogenolysis. The aqueous extract also slightly inhibited (18.1%) the 
intestinal absorption of glucose in rats. 
 Annona squamosa contains acetogenins, squamosin B, flavonoids, 
quercetin, reticulatain69, as its phytochemical constituents, which may be 
causing the anti diabetic effect. 
 Similar to many chronic diseases, diabetes mellitus is the cause and 
effect of elevated levels of reactive oxygen species (ROS). The ROS in 
low levels are important to maintain immunity, cause cellular maturation 
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and cell signaling. Its harmful effects include oxidative stress and 
metabolic derangement. 
 Chronic hyperglycemia stimulates ROS formation through 
oxidative phosphorylation, NAD(P)H oxidase, lipooxygenase, 
cytochrome P450 monooxygenase, glucose auto oxidation. The normal 
pancreatic beta cells contain minimal amounts of antioxidants only and 
hence their partial destruction (or) dysfunction in diabetes, makes them 
more susceptible to damage, than other tissues70. Hence, a drug with 
antioxidant property may have a dual effect on the outcome of diabetes 
management. 
 In vitro studies, proved that the leaves of Annona squamosa, have a 
free radical scavenging activity of 1, 1, - Diphenyl -2- Picryl Hydrazyl 
(DPPH) radical. The Oxygen Radical Absorbance Capacity (ORAC) 
assay, also quantitated the inhibition percentage of free radicals and the 
length of inhibition time in Annona extracts, which were proven 
significant71. In vitro studies on hexane extract of Annona leaves, showed 
inhibition of PTP1B (Protein Tyrosine Phosphatase 1B) in a dose 
dependant manner. The normal function of PTP1B is negative regulation 
of signaling of insulin. This is achieved through dephosphorylation of  
IR-beta (Insulin receptor beta) and IRS-1 (Insulin Receptor Substrate 1). 
The inhibition of PTP1B causes disinhibition of insulin secretion, thereby 
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activating downstream cellular events and increasing P13 kinase 
dependant increase in glucose uptake into the cells. The in vitro study 
was followed by treatment of ob/ob mice with the herbal extract, which 
improved glucose tolerance and lowered the triglyceride levels72. A 
further fractionation of potential bio active molecules might be needed to 
further elucidate the possible links in mechanism of action of Annona. 
 Diabetes mellitus inevitably leads to chronic glomeruloscelerosis 
and renal failure. So, provision of a drug, that is renoprotective in 
diabetes can be an added benefit. In a study, the aqueous extract of 
Annona squamosa, was found to lower the plasma urea, uric acid and 
creatinine levels in diabetic rats with impaired renal function. This was 
postulated to be the effect of the leaf extract on Super Oxide Dismutase 
(SOD)73. 
 In a 10 days study, it was found to increase the levels of renal SOD 
activity, which is an antioxidant, hence protecting the kidney from 
ischemia and renal failure. 
 In summary, increased mRNA expression of GLUT4 in peripheral 
tissues, the insulin releasing property, free radical scavenging property, 
inhibition of intestinal absorption of glucose and inhibition of PTP1B, 
might be responsible for the antihyperglycemic activity of Annona, 
leading to a statistically significant fall in the fasting blood glucose levels. 
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CONCLUSION 
Diabetes mellitus is an economic and social burden in India. 
Urbanisation and lack of physical activity are important contributory 
factors in pushing diabetes into the verge of becoming an 
epidemic.Diabetic complications have also increased manifold despite 
advances in the medical field and they contribute significantly to overall 
morbidity and mortality. The early age of onset and co occurrence of 
obesity has further complicated the disease outcome. 
Sensitive screening procedures and awareness regarding the 
disease and its complications will go a long way in curtailing diabetes. 
Pharmacotherapy is one of the pillars for treatment of diabetes.  
Even though umpteen antidiabetic drugs are in the market, no drug 
is free from adverse effects. Patient compliance is decreased due to their 
various side effects. Hence search for a “near ideal”drug exhibiting better 
safety and tolerability, which provides good glycemic control continues. 
Many effective drugs have come from botanical sources.Various 
parts of Allium cepa, Allium sativum and many other are considered to 
have antihyperglycemic activity. In this study, Annona squamosa leaf 
extract which was widely used in folklore medicine for several ailments 
was evaluated for its antihyperglycemic effect in albino rats. 
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-92-It was observed that annona leaf extract at 300 mg/kg and 600 mg/kg 
led to a statistically significant fall in blood glucose level in diabetic rats 
when compared with the control group. 
Fractionation of the active principle and further studies on animals 
of higher phylogenetic scale is needed in the near future, to elucidate the 
mechanism of action and confirm the antihyperglycemic activity of 
Annona squamosa. 
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MASTER CHART 
 
 
 
 
 
 
 
 
 
  
MASTER CHART 
 
The  blood glucose levels in  nondiabetic rats in mg/dl - baseline 
S. No. Control Standard T1 T2 
1 130 111 112 113 
2 115 124 114 108 
3 117 134 118 130 
4 108 106 128 104 
5 152 113 100 107 
6 81 129 108 113 
 
 
                                               
 
 
 
 
 
 
 
  
The blood glucose levels in diabetic rats in mg/dl on day 1 
 
S. No. Control Standard T1-300mg/kg 
T2- 
600mg/kg 
RAT- 1 489 523 589 587 
RAT- 2 420 554 574 593 
RAT -3 436 545 592 589 
RAT -4 465 560 565 547 
RAT -5 445 586 594 564 
RAT -6 472 578 579 583 
 
 
 
 
 
 
 
 
 
 
 
  
The blood glucose levels in diabetic rats in mg/dl on day 7 
 
S. No. Control Standard T1-300mg/kg 
T2- 
600mg/kg 
RAT -1 453 354 424 385 
RAT -2 476 410 443 364 
RAT -3 488 425 393 370 
RAT -4 517 378 398 451 
RAT -5 481 395 410 435 
RAT -6 490 402 387 385 
 
 
 
 
 
 
 
 
 
 
  
              The blood glucose levels in diabetic rats in mg/dl on day 14 
 
S. No. Control Standard T1-300mg/kg T2- 600mg/kg 
RAT -    1 435 98 90 114 
RAT-  2 446 102 77 103 
RAT- 3 459 86 131 85 
RAT -4 447 117 105 74 
RAT-5 464 71 97 93 
RAT-6 468 94 98 110 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
ABBREVIATION 
 
 
 
 
 
 
 
  
ABBREVIATION 
 
 
DM – DIABETES MELLITUS 
ROS – REACTIVE OXYGEN SPECIES 
JNK/SAPK – c-JUN N-TERMINAL KINASE 
NF-Κb – NUCLEAR FACTOR kappa B 
MAPK – MITOGEN ACTIVATED PROTEIN KINASE
GL – GLIBENCLAMIDE 
ATP – ADENOSINE TRIPHOSPHATE 
Ca2+ – CALCIUM 
STZ – STREPTOZOTOCIN 
NAD – NICOTINAMIDE ADENINE 
DINUCLEOTIDE 
HLA – HUMAN LEUKOCYTE ANTIGEN 
GLUT2 – GLUCOSE TRANSPORTER 2 
GLP – GLUCAGON LIKE PEPTIDE 
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